Intravenous Immunoglobulin After Relapse in Vasculitis
Intravenous Immunoglobulin After Relapse in Vasculitis
The aim of this study is to study the efficacy of intravenous immunoglobulins for inducing
 remission in patients relapsing of systemic vasculitides.
The aim of this study will assess the effects of intravenous immunoglobulin in ANCA+
 vasculitides (Microscopic Polyangiitis, Wegener's granulomatosis and Churg-Strauss syndrome)
 who relapse under corticosteroid and immunosuppressant therapies or after one year post
 treatment.
Inclusion Criteria:

 -  Wegener's granulomatosis, Microscopic polyangiitis and Churg-Strauss syndrome
 (satisfying ACR or chapel Hill classification) relapsing either under corticosteroid
 and immunosuppressant therapies or after one year post treatment

 -  Age > 18 years old

 -  Written informed consent

 Exclusion Criteria:

 -  Systemic vasculitides not previously treated with corticosteroid and
 immunosuppressant(s)

 -  Systemic vasculitides treated with corticosteroids and immunosuppressant therapies,
 but with treatment cessation more than 12 months ago

 -  Polyarteritis nodosa

 -  Absence of poor prognosis criteria (according to FFS)

 -  Nephritis ± renal impairment

 -  Cancer or malignancy

 -  Psychiatric disease, lack of compliance

 -  Age under 18 years old

 -  Lack of written informed consent

 -  Other vasculitides (post viral infection and skin localisation)